Skip to main content

Avoro Capital Advisors LLC

13F filer · CIK 0001633313
Reported Aug 14, 2026
Net seller this quarter
13F portfolio value$11.1BU.S. long equity reported on 13F
Positions262 new · 6 closed
Net flow last quarter-$816MBuys minus sells
Top 10 positions weight79.5%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 14, 202626 positions
UTHRUNITED THERAPEUTICS Corp$1.51B13.52%6.51%+5.6%Q4 2020
ASNDAscendis Pharma A/S$1.36B12.24%8.25%+1.0%Q3 2016
KRYSKrystal Biotech, Inc.$1.07B9.64%9.76%Not reportedQ4 2021
MDGLMadrigal Pharmaceuticals, Inc.$984M8.84%7.94%+0.8%Q2 2018
ARGXArgenx SE$928M8.33%1.62%Not reportedQ2 2017
ARWRArrowhead Pharmaceuticals, Inc.$926M8.31%8.05%+6.1%Q4 2014
KYMRKymera Therapeutics, Inc.$857M7.70%9.03%Not reportedQ3 2020
RVMDRevolution Medicines, Inc.$430M3.86%1.07%-2.0%Q1 2020
CYTKCytokinetics Inc$426M3.82%4.02%+50.0%Q2 2016
CELCCelcuity Inc.$356M3.19%6.95%+0.7%Q4 2025
GPCRStructure Therapeutics Inc.$352M3.16%3.07%Not reportedQ3 2023
XENEXenon Pharmaceuticals Inc.$349M3.13%5.97%Not reportedQ2 2018
DFTXDefinium Therapeutics, Inc.$338M3.04%5.35%+43.8%Q1 2026
QUREuniQure N.V.$310M2.78%9.70%+12.9%Q1 2015
VERAVera Therapeutics, Inc.$246M2.21%7.97%-2.8%Q1 2024
TSHATaysha Gene Therapies, Inc.$163M1.46%7.34%+10.1%Q3 2023
OCULOcular Therapeutix, Inc$123M1.11%5.71%+1.8%Q1 2024
DMRADamora Therapeutics, Inc.$98.4M0.88%6.13%Not reportedQ1 2026
COAGHemab Therapeutics Holdings, Inc.$70.7M0.63%4.12%NewQ2 2026
GHRSGH Research PLC$48.4M0.43%2.90%Not reportedQ4 2025
VRDNViridian Therapeutics, Inc.\DE$45.9M0.41%2.21%+66.7%Q4 2025
SEPNSepterna, Inc.$44.8M0.40%2.93%Not reportedQ4 2024
AVTXAvalo Therapeutics, Inc.$43.1M0.39%4.41%+65.5%Q1 2026
FTHFaeth Therapeutics, Inc.$36.1M0.32%5.59%NewQ2 2026
WHWKWhitehawk Therapeutics, Inc.$13.1M0.12%5.00%Not reportedQ3 2021
LXEOLexeo Therapeutics, Inc.$6.93M0.06%1.89%-20.6%Q4 2025
Q1 2026Reported May 15, 202630 positions
UTHRUNITED THERAPEUTICS Corp$1.56B15.34%6.24%+0.9%Q4 2020
ASNDAscendis Pharma A/S$1.16B11.39%8.17%-1.0%Q3 2016
MDGLMadrigal Pharmaceuticals, Inc.$952M9.36%7.89%+0.6%Q2 2018
KRYSKrystal Biotech, Inc.$746M7.34%9.81%Not reportedQ4 2021
ARGXArgenx SE$730M7.18%1.62%+1.0%Q2 2017
ARWRArrowhead Pharmaceuticals, Inc.$671M6.60%7.61%+0.7%Q4 2014
KYMRKymera Therapeutics, Inc.$623M6.12%9.10%Not reportedQ3 2020
APLSApellis Pharmaceuticals, Inc.$492M4.84%9.55%Not reportedQ4 2017
CNTACentessa Pharmaceuticals PLC$454M4.47%7.39%-21.5%Q2 2021
CELCCelcuity Inc.$385M3.79%6.98%+8.5%Q4 2025
XENEXenon Pharmaceuticals Inc.$336M3.31%5.98%+6.5%Q2 2018
GPCRStructure Therapeutics Inc.$316M3.11%3.07%Not reportedQ3 2023
TERNTerns Pharmaceuticals, Inc.$300M2.95%4.93%+30.9%Q4 2025
VERAVera Therapeutics, Inc.$237M2.33%9.21%Not reportedQ1 2024
RVMDRevolution Medicines, Inc.$228M2.24%1.17%+8.0%Q1 2020
CYTKCytokinetics Inc$220M2.16%2.71%Not reportedQ2 2016
OCULOcular Therapeutix, Inc$104M1.03%5.63%+14.3%Q1 2024
DMRADamora Therapeutics, Inc.$98M0.96%6.27%NewQ1 2026
QUREuniQure N.V.$97.4M0.96%9.45%-3.1%Q1 2015
TSHATaysha Gene Therapies, Inc.$97M0.95%7.55%Not reportedQ3 2023
DFTXDefinium Therapeutics, Inc.$94.5M0.93%4.81%NewQ1 2026
SLNOSoleno Therapeutics Inc$77M0.76%4.45%-20.7%Q4 2023
ALKSAlkermes plc.$42.4M0.42%0.72%-14.3%Q4 2024
SEPNSepterna, Inc.$32.1M0.32%2.98%Not reportedQ4 2024
VRDNViridian Therapeutics, Inc.\DE$29.3M0.29%1.46%Not reportedQ4 2025
GHRSGH Research PLC$25.3M0.25%2.90%Not reportedQ4 2025
AVTXAvalo Therapeutics, Inc.$21.1M0.21%5.72%NewQ1 2026
LXEOLexeo Therapeutics, Inc.$10.8M0.11%2.53%-43.2%Q4 2025
WHWKWhitehawk Therapeutics, Inc.$9.83M0.10%6.04%Not reportedQ3 2021
MNKDMannkind Corp$5.39M0.05%0.71%-50.5%Q4 2020
Q4 2025Reported Mar 16, 202632 positions
UTHRUNITED THERAPEUTICS Corp$1.27B12.48%5.97%+28.9%Q4 2020
ASNDAscendis Pharma A/S$1.09B10.71%8.25%0.0%Q3 2016
MDGLMadrigal Pharmaceuticals, Inc.$1.05B10.35%7.91%-1.4%Q2 2018
ARGXArgenx SE$833M8.18%1.60%Not reportedQ2 2017
KRYSKrystal Biotech, Inc.$712M7.00%9.90%+4.0%Q4 2021
ARWRArrowhead Pharmaceuticals, Inc.$705M6.93%7.73%-2.5%Q4 2014
KYMRKymera Therapeutics, Inc.$582M5.72%9.19%+17.7%Q3 2020
GPCRStructure Therapeutics Inc.$456M4.48%3.08%+27.2%Q3 2023
RNAMAvidity Biosciences, Inc.$393M3.87%3.61%-28.7%Q2 2020
CNTACentessa Pharmaceuticals PLC$364M3.58%9.75%+34.7%Q2 2021
CELCCelcuity Inc.$310M3.05%6.45%NewQ4 2025
APLSApellis Pharmaceuticals, Inc.$307M3.02%9.65%Not reportedQ4 2017
VERAVera Therapeutics, Inc.$298M2.93%9.21%-5.2%Q1 2024
XENEXenon Pharmaceuticals Inc.$243M2.39%6.78%+0.5%Q2 2018
TERNTerns Pharmaceuticals, Inc.$176M1.73%3.87%NewQ4 2025
RVMDRevolution Medicines, Inc.$173M1.70%1.10%Not reportedQ1 2020
QUREuniQure N.V.$147M1.45%9.87%+38.4%Q1 2015
SLNOSoleno Therapeutics Inc$134M1.32%5.55%+12.5%Q4 2023
OCULOcular Therapeutix, Inc$131M1.29%4.99%+5.2%Q1 2024
TSHATaysha Gene Therapies, Inc.$119M1.17%7.61%Not reportedQ3 2023
MNMDDefinium Therapeutics, Inc.$67M0.66%Not reportedNewQ4 2025
PTCTPTC Therapeutics, Inc.$52M0.51%0.84%Not reportedQ2 2017
VRDNViridian Therapeutics, Inc.\DE$46.7M0.46%1.47%NewQ4 2025
ORKAOruka Therapeutics, Inc.$40.4M0.40%2.74%Not reportedQ3 2025
ALKSAlkermes plc.$39.2M0.39%0.85%-37.5%Q4 2024
APGEApogee Therapeutics, Inc.$37.7M0.37%0.73%NewQ4 2025
SEPNSepterna, Inc.$37.3M0.37%2.99%Not reportedQ4 2024
LXEOLexeo Therapeutics, Inc.$32.8M0.32%4.52%NewQ4 2025
MNKDMannkind Corp$25.2M0.25%1.44%-0.6%Q4 2020
GHRSGH Research PLC$22.9M0.22%2.90%NewQ4 2025
INCYIncyte Corp$13.3M0.13%0.07%Not reportedQ4 2017
WHWKWhitehawk Therapeutics, Inc.$6.9M0.07%6.04%Not reportedQ3 2021
Q3 2025Reported Nov 14, 202530 positions
ASNDAscendis Pharma A/S$1.02B13.13%8.42%+2.6%Q3 2016
UTHRUNITED THERAPEUTICS Corp$848M10.96%4.71%-14.7%Q4 2020
MDGLMadrigal Pharmaceuticals, Inc.$841M10.87%8.07%-2.2%Q2 2018
ARGXArgenx SE$730M9.44%1.63%-15.7%Q2 2017
KRYSKrystal Biotech, Inc.$490M6.34%9.58%+4.4%Q4 2021
ARWRArrowhead Pharmaceuticals, Inc.$376M4.86%8.03%+2.8%Q4 2014
KYMRKymera Therapeutics, Inc.$359M4.65%8.85%-3.1%Q3 2020
MRUSMerus N.V.$334M4.31%4.67%+12.3%Q1 2021
RNAMAvidity Biosciences, Inc.$333M4.31%5.21%+8.4%Q2 2020
APLSApellis Pharmaceuticals, Inc.$277M3.58%9.66%Not reportedQ4 2017
CNTACentessa Pharmaceuticals PLC$262M3.39%8.04%+116.2%Q2 2021
QUREuniQure N.V.$259M3.35%7.15%+22.6%Q1 2015
XENEXenon Pharmaceuticals Inc.$217M2.80%7.00%Not reportedQ2 2018
AKROAkero Therapeutics, Inc.$188M2.43%4.94%+13.0%Q3 2023
VERAVera Therapeutics, Inc.$180M2.33%9.73%-1.4%Q1 2024
SLNOSoleno Therapeutics Inc$174M2.25%4.80%+25.8%Q4 2023
GPCRStructure Therapeutics Inc.$144M1.87%2.83%Not reportedQ3 2023
TRMLTourmaline Bio, Inc.$122M1.58%9.95%Not reportedQ4 2023
OCULOcular Therapeutix, Inc$120M1.55%5.86%+38.5%Q1 2024
FOLDAmicus Therapeutics, Inc.$118M1.53%4.87%-16.5%Q4 2014
ETNB89bio, Inc.$93.9M1.21%4.31%-5.4%Q4 2024
TSHATaysha Gene Therapies, Inc.$71M0.92%7.92%Not reportedQ3 2023
ALKSAlkermes plc.$67.2M0.87%1.36%-22.8%Q4 2024
ORKAOruka Therapeutics, Inc.$25.6M0.33%2.76%NewQ3 2025
SEPNSepterna, Inc.$25.2M0.33%3.00%+8.1%Q4 2024
MNKDMannkind Corp$24M0.31%1.46%-23.6%Q4 2020
MLTXMoonLake Immunotherapeutics$14.3M0.19%3.80%-51.8%Q2 2023
BCRXBiocryst Pharmaceuticals Inc$9.49M0.12%0.59%-72.2%Q3 2016
WHWKWhitehawk Therapeutics, Inc.$5.41M0.07%6.05%Not reportedQ3 2021
TNGXTango Therapeutics, Inc.$4.58M0.06%0.49%Not reportedQ3 2021
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.